Two Months into a Reverse Merger, Where Does Seelos Therapeutics Stand Now?
NEW YORK, NY / ACCESSWIRE / April 2, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Seelos TherapeuticsInc. (SEEL) is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders.
Seelos successfully transitioned into a publicly traded company on Nasdaq by completing its reverse merger with Apricus BioSciences, Inc. on January 24, 2019.
Read about the merger synergies and the current pipeline status here READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/seelos-therapeutics/
In February, Seelos acquired the worldwide development and commercial rights to Bioblast's proprietary trehalose 90 mg/mL IV solution and all inventory of the drug. Seelos has named this program SLS-005.
In March, Seelos acquired a license to technology developed at UCLA that relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein). Seelos has named this program SLS-007.
Get info on these programs and looks at near term milestones and catalysts READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/seelos-therapeutics/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
View source version on accesswire.com:
https://www.accesswire.com/540820/Two-Months-into-a-Reverse-Merger-Where-Does-Seelos-Therapeutics-Stand-Now
